Stem cell startup proclaims ‘inflection point’ for medicine as mass production nears

image via TNW | The heart of techThe Next Web

August 7, 2025, 1:51 PM

• •Cellcolabs, a Swedish biotech company, is working to scale up stem cell therapies.
• •MSCs (mesenchymal stem cells) are being produced at the Karolinska Institute.
• •The goal is to make stem cell treatments affordable and widely available within the next decade.
• •Cellcolabs is developing bioreactors to increase MSC production.
• •Trials are underway to test MSCs for various conditions, with the aim of shifting healthcare towards prevention and improving healthy lifespans.

Cellcolabs, a Swedish biotech firm, believes stem cell therapies are on the verge of commercial viability, aiming to revolutionize medicine. Scientists at the Karolinska Institute are producing mesenchymal stem cells (MSCs) with the goal of making these treatments accessible and affordable. The company is developing bioreactors to scale up production, with a target launch in 2028. Trials are underway to explore MSCs for various health conditions, with a focus on prevention and extending healthy lifespans.

Read original article